Loading
Archives of Gastroenterology Research
ISSN: 2692-5427
Neurofibromatosis Type 1 and Crohn’s Disease Association: Case Report
We described a 15-year-old- a boy who presented with neurofibromatosis type 1 and Crohn’s disease. Neurofibromatosis 1 (NF1) is the most common form of NF, affecting 1 in 3000 individuals. Crohn’s disease is one of the inflammatory bowel diseases. Its incidence is significantly rising in Ireland. Concomitant association of NF1 and Crohn’s disease is a rare finding. This is the first case reported in the paediatric population.
Arch Gastroenterol Res, 2023, Volume 4, Issue 1, p1-3 | DOI: 10.33696/Gastroenterology.4.041Exploring the Use of Point of Care Ultrasound in Screening for Non-Alcoholic Fatty Liver Disease: A Systematic Literature Review and Meta-Analysis
Non-alcoholic fatty liver disease (NAFLD) is a major cause of cirrhosis and liver failure globally. Despite its broad impact, screening recommendations for NAFLD remain varied based between gastrointestinal societies. Point of care ultrasound (POCUS) has emerged as a new form of screening and diagnosing intrabdominal pathologies including NAFLD. We aimed to estimate the effectiveness of POCUS in screening for NAFLD
Arch Gastroenterol Res, 2023, Volume 4, Issue 1, p4-11 | DOI: 10.33696/Gastroenterology.4.042A Rare Endoscopic Finding: Gastric Diverticulum
A 40-year-old man received upper gastrointestinal endoscopic scan during a health check-up. There was no history suggestive of Helicobacter pylori eradication, reflux esophagitis, peptic ulcer disease and upper abdominal surgery. Endoscopy revealed a wide-mouthed diverticulum of the size of 1.5 × 2 cm between the fundus and greater curvature of the stomach (Figure 1).
Arch Gastroenterol Res, 2023, Volume 4, Issue 1, p12-13 | DOI: 10.33696/Gastroenterology.4.043Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis
Liver fibrosis resulting from chronic liver injury can progress to cirrhosis and liver failure. Current treatments are limited, creating an urgent need for novel antifibrotic therapies. Multiple emerging approaches have shown preclinical promise in inhibiting liver fibrogenesis or stimulating regeneration, including artificial liver support, stem cell therapy, cell/gene therapy, nanomedicines, immunotherapy, and herbal medicines.
Arch Gastroenterol Res, 2023, Volume 4, Issue 1, p14-23 | DOI: 10.33696/Gastroenterology.4.044Advancements in Drug Delivery Systems for Natural Compounds Targeting Metabolic Disorders Associated with Inflammation
The global incidence of metabolic disorders is on the rise, posing a significant challenge to public health. With remarkable advancements in diagnostic tools and clinical procedures, our understanding of the etiology and underlying pathophysiology of these disorders has expanded considerably. Furthermore, the utilization of in vitro and in vivo experimental models, preceding clinical investigations, has catalyzed numerous breakthroughs in biomedicine, particularly in the identification and development of potential drug candidates for the management of metabolic disorders.
Arch Gastroenterol Res, 2023, Volume 4, Issue 1, p24-35 | DOI: 10.33696/Gastroenterology.4.045Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.